Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Infigratinib Promotes Clinical Activity in Patients With Chemo-Refractory, FGFR2+ Cholangiocarcinoma
January 17th 2021In a phase 2 clinical trial, the oral, FGFR1-3 selective tyrosine kinase inhibitor, infigratinib correlated with promising anticancer activity in addition to manageable safety as treatment of patients with chemotherapy-refractory cholangiocarcinoma whose tumors harbor FGFR2 fusions.
Read More
Ivosidenib Improves Overall Survival in Advanced IDH1+ Cholangiocarcinoma
January 17th 2021The final overall survival analysis of the phase 3 ClarIDHy trial demonstrated that treatment with ivosidenib tablets achieved a 21% reduction in the risk of death in patients with IDH1-mutant cholangiocarcinoma compared with placebo.
Read More
Step Counts Correlated With QoL With SM-88 in Metastatic Pancreatic Cancer
January 16th 2021Step counts appeared to correlate with self-reported quality of life during the first 2 weeks of treatment with SM-88 in patients with metastatic pancreatic cancer, the results of a preliminary exploratory analysis from part 2 of the phase 2/3 TYME-88-Panc trial showed.
Read More
Frontline Bemarituzumab Doublet Prolongs Survival in Advanced FGFR2b+ Gastric/GEJ Cancer
January 16th 2021In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.
Read More
Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer
January 15th 2021Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer, according to data from the phase 3 JCOG 1109 trial that were virtually presented at the 2021 Gastrointestinal Cancers Symposium.
Read More
FDA Approves Trastuzumab Deruxtecan for HER2+ Gastric/GEJ Cancer
January 15th 2021The FDA has approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
Read More
Lenvatinib/Pembrolizumab Deemed Safe and Effective in Select GI Cancers
January 15th 2021In multiple gastrointestinal tumor types, the combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile, according to data presented at the 2021 ASCO Gastrointestinal Cancers Symposium.
Read More
Nivolumab Shows QoL Improvement in Esophageal and Gastroesophageal Cancers
January 15th 2021Esophageal-specific and general quality of life was improved in patients with esophageal/gastroesophageal cancer who received nivolumab in the Checkmate 577 clinical trial, according to subgroup analysis data presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
Read More
Pembrolizumab/Trastuzumab Regimen Effective in Treating HER2-Positive Advanced Gastric, GEJ Cancer
January 15th 2021The addition of pembrolizumab and trastuzumab to the combination cisplatin plus capecitabine was able to effectively treat HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of PD-L1 expression in the phase 1b/2 PANTHERA trial.
Read More
Camrelizumab Combo Elicits Encouraging Efficacy in Second-Line Esophageal Squamous Cell Carcinoma
January 15th 2021Camrelizumab in combination with apatinib demonstrated encouraging clinical efficacy as a second-line treatment of patients with esophageal squamous cell carcinoma and demonstrated acceptable safety in a single-arm, open-label phase 2 clinical trial.
Read More
Pembrolizumab Plus Lanreotide Induces High Response Rates in GEP Neuroendocrine Tumors
January 15th 2021Roughly 40% of patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors treated with pembrolizumab in combination with lanreotide achieved stable disease, according to results from the phase 1b/2 PLANET clinical trial presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancer Symposium.
Read More
Priority Review Granted to Pembrolizumab Combo in Metastatic Esophageal and GEJ Cancer
December 17th 2020The FDA granted a Priority Review designation to pembrolizumab for potential approval with platinum and fluoropyrimidine-based chemotherapy as frontline treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction.
Read More
Paradigm Pivots in Neoadjuvant Direction: Expert Insights on World Pancreatic Cancer Day
November 19th 2020Following a long history with minimal advances, neoadjuvant therapy provides hope on future avenues to further explore in order to continue improving outcomes for patients with pancreatic cancer.
Read More
Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors
November 17th 2020In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.
Read More
Marshall Recognizes Need for Collaboration During Pancreatic Cancer Awareness Month
November 13th 2020In an interview with Targeted Oncology, John L. Marshall, MD, provided an overview of the evolution of treatments for patients with pancreatic cancer, as well as the current therapeutic approaches for these patients and what’s next for this treatment paradigm.
Read More
First-In-Class Targeted Therapy Shows Survival Benefit Advanced Gastric/GEJ Adenocarcinoma Subset
November 11th 2020Three efficacy end points met pre-specified statistical significance in the phase 2 FIGHT study of bemarituzumab plus modified FOLFOX6 in patients with FGFR2b-positive non-HER2-positive frontline advanced gastric or gastroesophageal junction cancer.
Read More
Irinotecan Monotherapy Appears as Efficacious as Capecitabine Combo in Advanced Gallbladder Cancer
November 11th 2020In an interview with Targeted Oncology, Anant Ramaswamy, MD, discussed the findings from the phase 2 study of capecitabine plus irinotecan compared with irinotecan alone as treatment of patients with advanced gallbladder cancer.
Read More
FDA Grants Orphan Drug Designation to Novel Monoclonal Antibody in Multiple GI Malignancies
October 15th 2020An Orphan Drug Designation had been granted by the FDA to the CD40 antagonistic monoclonal antibody, APX005M for the treatment esophageal and gastroesophageal junction cancer, as well as for the treatment of patients with pancreatic cancer.
Read More
Expert Highlights Importance of Biomarker Testing in Pancreatic Cancer
October 7th 2020At ISGIO 2020, Michael J. Pishvaian, MD, PhD, discussed the importance of using standard-of-care chemotherapy and to test for actionable mutations in patients with pancreatic cancers, which can identify ways to individualize therapy for these patients.
Read More